Ligand Pharmaceuticals (LGND) risk factors, FY2024 10-K

Risks Related to Our Business Operations and Reliance on Third Parties

1. 01Future revenue based on Kyprolis, Qarziba, Filspari, Evomela, Teriparatide and Rylaze, as well as royalties from our other partnered products, may be lower than expected
2. 02Future revenue from sales of Captisol material to our license partners may be lower than expected
3. 03A supply chain interruption may impact our ability to obtain Captisol material
4. 04Future revenue from royalties on Captisol partnered products may be lower than expected
5. 05Our collaboration partners may change their strategy or the focus of their development and commercialization efforts with respect to our partnered programs, and the success of our partnered programs could be adversely affected
6. 06Our product candidates, and the product candidates of our partners, face significant development and regulatory hurdles prior to partnering and/or marketing which could delay or prevent licensing, sales-based royalties and/or milestone revenue
7. 07Biopharmaceutical products are subject to sales risks
8. 08New products and technologies of other companies may render some or all of our or our potential milestone and royalty providers’ product candidates noncompetitive or obsolete
9. 09We face competition in acquiring existing “passive” royalties and locating suitable passive royalties to acquire
10. 10Information available to us about the biopharmaceutical products underlying the royalties we purchase and invest in may be limited and, therefore, our ability to analyze each product and its potential future cash flow may be similarly limited
11. 11A significant portion of our future income is dependent upon numerous royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns
12. 12The insolvency of any of our partners or third-parties who are developing or commercializing products to which we have economic rights could adversely affect our receipt of cash flows on the related milestones or royalties that we own
13. 13The commercial success of our product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payers and others in the medical community

Risks Related to Intellectual Property

1. 14Third party intellectual property may prevent us or our partners from developing our potential products; our and our partners’ intellectual property may not prevent competition; and any intellectual property issues may be expensive and time consuming to resolve
2. 15Issued patents directed to our platform and technology could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad
3. 16patents and patent applications or licensed patents and patent applications has been found, which could be used by a third party to challenge their validity, or prevent a patent from issuing from a pending patent application
4. 17The validity, scope and enforceability of any patents that cover our partners’ biologic product candidate can be challenged by third parties
5. 18Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products, platform and technology
6. 19We may be subject to claims challenging the inventorship of our patents and other intellectual property
7. 20If we are unable to protect the confidentiality of our information and our trade secrets, the value of our technology could be materially and adversely affected and our business could be harmed

Risks Related to Government Regulation and Legal Proceedings

1. 21Market acceptance and sales of any approved product will depend significantly on the availability and adequacy of coverage and reimbursement from third-party payors and may be affected by existing and future healthcare reform measures
2. 22If we or our commercialization partners market products in a manner that violates healthcare laws, we may be subject to civil or criminal penalties
3. 23Changes in and actual or perceived failures to comply with applicable data privacy, security and protection laws, regulations, standards and contractual obligations may adversely affect our business, operations and financial performance
4. 24The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we or our partners are ultimately unable to obtain regulatory approval for product candidates, our business will be substantially harmed
5. 25Pharmaceutical products are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense
6. 26If plaintiffs bring product liability lawsuits against us or our partners, we or our partners may incur substantial liabilities and may be required to limit commercialization of our approved products and product candidates
7. 27We face risks related to handling of hazardous materials and other regulations governing environmental safety
8. 28We may also be subject to other laws and regulations not specifically targeting the healthcare industry

Risk Related to Our Strategic Transactions

1. 29Any difficulties from strategic acquisitions and other M&A transactions could adversely affect our stock price, operating results and results of operations
2. 30The Pelthos business may suffer from uncertain business operations if we do not consummate a transaction or enter into commercial partnerships involving Pelthos
3. 31Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
4. 32Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations
5. 33Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition, or results of operations
6. 34Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations
7. 35The OmniAb Separation and OmniAb Distribution may expose Ligand to potential liabilities arising out of state and federal fraudulent conveyance laws and legal dividend requirements
8. 36The occurrence of a catastrophic disaster could disrupt our business, damage our facilities beyond insurance limits, increase our costs and expenses, or we could lose key data which could cause us to curtail or cease operations
9. 37We rely on information technology system and any failure, inadequacy, interruption or security lapse of our information technology systems, including any cyber security incidents, could harm our ability to operate our business effectively
10. 38We use or draw down on our Credit Agreement or use other debt in connection with our capital deployment, which magnifies the potential for loss if the royalties acquired do not generate sufficient income to us
11. 39Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse impact on our results of operations and the market value of our common stock
12. 40Our investments are subject to market and credit risks that could diminish their value and these risks could be greater during periods of extreme volatility or disruption in the financial and credit markets, which could adversely impact our business, financial condition, results of operations, liquidity and cash flows
13. 41Our charter documents and concentration of ownership may hinder or prevent change of control transactions
14. 42Our stock price has been volatile and could experience a sudden decline in value
15. 43financial reporting as of the end of our most recent fiscal year. In addition, our independent registered public accounting firm is required to provide a related attestation report on our internal control over financial reporting
16. 44Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations
17. 45Our business is subject to risks arising from pandemic and epidemic diseases
18. 46we fail to deliver Captisol timely, interruption or delays to discovery and development pipelines and difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols
19. 47If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline
20. 48Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations
21. 49The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of the royalties that we hold